Zobrazeno 1 - 10
of 76
pro vyhledávání: '"Joanna Romejko‐Jarosinska"'
Autor:
Małgorzata Sokołowska-Wojdyło, Berenika Olszewska, Ewa Chmielowska, Ewa Robak, Monika Prochorec-Sobieszek, Grażyna Kamińska-Winciorek, Joanna Maj, Anna Kowalczyk, Adam Reich, Aleksandra Lesiak, Joanna Narbutt, Jacek Szepietowski, Anna Jolanta Woźniacka, Agnieszka Barbara Owczarczyk-Saczonek, Joanna Romejko-Jarosińska, Agnieszka Giza, Roman Nowicki, Andrzej Kazimierz Jaworek, Jan Maciej Zaucha
Publikováno v:
Przegląd Dermatologiczny, Vol 110, Iss 6, Pp 647-674 (2024)
Primary cutaneous lymphomas are a heterogeneous group of rare lymphoproliferative diseases that are initially limited to the skin but potentially also involve the lymph nodes, blood, and occasionally visceral organs. They develop from mature T cells,
Externí odkaz:
https://doaj.org/article/52795847d810475a985641ed3942597e
Autor:
Elżbieta Kalicińska, Agnieszka Giza, Jan Maciej Zaucha, Sebastian Giebel, Dagmara Zimowska‐Curyło, Iga Andrasiak, Wojciech Spychałowicz, Jerzy Wojnar, Andrzej Balcerzak, Joanna Romejko‐Jarosińska, Ewa Paszkiewicz‐Kozik, Wanda Knopińska‐Posłuszny, Justyna Rybka, Paula Jabłonowska, Tomasz Wróbel
Publikováno v:
Cancer Medicine, Vol 12, Iss 3, Pp 3036-3045 (2023)
Abstract Objective To investigate the prevalence of histopathological subtypes, the clinical stage at presentation and treatment modalities in Polish patients with orbital lymphoma (OL) and to determine prognostic outcomes. Methods The retrospective
Externí odkaz:
https://doaj.org/article/8bfcff17849f4c5cb3b258376f77adc4
Autor:
Joanna Romejko-Jarosinska, Beata Ostrowska, Anna Dabrowska-Iwanicka, Katarzyna Domanska-Czyz, Grzegorz Rymkiewicz, Ewa Paszkiewicz-Kozik, Robert Konecki, Anna Borawska, Agnieszka Druzd-Sitek, Elzbieta Lampka, Wlodzimierz Osiadacz, Michal Osowiecki, Lidia Popławska, Monika Swierkowska, Lukasz Targonski, Joanna Tajer, Grazyna Lapinska, Malwina Smorczewska, Jan Walewski
Publikováno v:
Scientific Reports, Vol 12, Iss 1, Pp 1-11 (2022)
Abstract Primary mediastinal B-cell lymphoma (PMBL) is currently curable in 85–95% of patients. Treatment regimens frequently used include RCHOP ± radiotherapy, DAEPOCH-R, or occasionally more intensive protocols. Here we present results of treatm
Externí odkaz:
https://doaj.org/article/390d2e0cb00f467e8bbd36aeef3cedd8
Autor:
Beata Ostrowska, Katarzyna Domanska‐Czyz, Joanna Romejko‐Jarosinska, Michal Osowiecki, Lukasz Targonski, Lidia Poplawska, Robert Konecki, Martyna Kotarska, Marcin Szymanski, Anna Borawska, Monika Swierkowska, Anna Dabrowska‐Iwanicka, Agnieszka Druzd‐Sitek, Ewa Paszkiewicz‐Kozik, Ewa Mroz‐Zycinska, Joanna Tajer, Elzbieta Wojciechowska‐Lampka, Wlodzimierz Osiadacz, Grzegorz Rymkiewicz, Grazyna Lapinska, Marta Wojewodzka‐Mirocha, Wojciech Michalski, Jan Walewski
Publikováno v:
British Journal of Haematology. 201:663-672
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::08131a297e3c6b7acd604bf250485db4
https://doi.org/10.1111/bjh.18687
https://doi.org/10.1111/bjh.18687
Autor:
Ali Bazarbachi, Ariane Boumendil, Hervé Finel, Irma Khvedelidze, Joanna Romejko-Jarosinska, Alina Tanase, Saad Akhtar, Tarek Ben Othman, Mohammad Ma’koseh, Boris Afanasyev, Jean Cheikh, Javier Briones, Zafer Gülbas, Rose-Marie Hamladji, Tugrul Elverdi, Didier Blaise, Carmen Martínez, Eleonora Alma, Kazimierz Halaburda, Aida Botelho Sousa, Bertram Glass, Steven Robinson, Silvia Montoto, Anna Sureda
Publikováno v:
LEUKEMIA
r-IIB SANT PAU. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pau
instname
r-IIB SANT PAU. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pau
instname
Hodgkin lymphoma (HL) patients who relapse after autologous-stem-cell- transplantation (auto-SCT) have traditionally had a poor prognosis. We analyzed 1781 adult HL patients who relapsed between 2006 and 2017 after a first auto-SCT. The 4-year overal
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5216f321738ff234e1529580d1a25fe0
https://doi.org/10.1038/s41375-022-01563-8
https://doi.org/10.1038/s41375-022-01563-8
Autor:
Deborah Ricci, George Mulligan, Dixie-Lee Esseltine, Andrew Cakana, Pier Luigi Zinzani, Ofer Shpilberg, Michael Crump, Sven de Vos, Joanna Romejko-Jarosinska, Adriana Teixeira, Simon Rule, Fritz Offner, Jiri Mayer, Adriana Scheliga, Xiaonan Hong, Evgenii A. Osmanov, Michael E. Schaffer, Helgi van de Velde, Yusri A. Elsayed, Panteli Theocharous, Alice Shapiro, Dana Gaffney, Reyna Favis, Jayaprakash D. Karkera, Erin D. Henitz, Weimin Li, Bertrand Coiffier
Supplementary Table 1 PDF file 55K, Cut-points for protein markers used in different analyses. Cut-points selected for pair-wise comparisons were chosen to reduce the total number of comparisons that would be done. Cut-points for the discovery/confir
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::245d4e67339bbfb730907a011ad4b739
https://doi.org/10.1158/1078-0432.22448841
https://doi.org/10.1158/1078-0432.22448841
Autor:
Deborah Ricci, George Mulligan, Dixie-Lee Esseltine, Andrew Cakana, Pier Luigi Zinzani, Ofer Shpilberg, Michael Crump, Sven de Vos, Joanna Romejko-Jarosinska, Adriana Teixeira, Simon Rule, Fritz Offner, Jiri Mayer, Adriana Scheliga, Xiaonan Hong, Evgenii A. Osmanov, Michael E. Schaffer, Helgi van de Velde, Yusri A. Elsayed, Panteli Theocharous, Alice Shapiro, Dana Gaffney, Reyna Favis, Jayaprakash D. Karkera, Erin D. Henitz, Weimin Li, Bertrand Coiffier
Supplementary Figure 1 PDF file 77K, Biomarker sample collection from the LYM-3001 intent-to-treat population
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4b9b8198920706057590a26c44b865fd
https://doi.org/10.1158/1078-0432.22448856
https://doi.org/10.1158/1078-0432.22448856
Autor:
Deborah Ricci, George Mulligan, Dixie-Lee Esseltine, Andrew Cakana, Pier Luigi Zinzani, Ofer Shpilberg, Michael Crump, Sven de Vos, Joanna Romejko-Jarosinska, Adriana Teixeira, Simon Rule, Fritz Offner, Jiri Mayer, Adriana Scheliga, Xiaonan Hong, Evgenii A. Osmanov, Michael E. Schaffer, Helgi van de Velde, Yusri A. Elsayed, Panteli Theocharous, Alice Shapiro, Dana Gaffney, Reyna Favis, Jayaprakash D. Karkera, Erin D. Henitz, Weimin Li, Bertrand Coiffier
Supplementary Table 4 PDF file 69K, OS, ORR, CR rate, and TTNT in all patients in the cross-validation model (see Supplementary Methods) who were positive or negative for the biomarker pair PSMB1 P11A (G allele) and low CD68 expression (≤50 CD68-po
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0df20422ab53789faea7f0b0ec0dc555
https://doi.org/10.1158/1078-0432.22448832
https://doi.org/10.1158/1078-0432.22448832
Autor:
Deborah Ricci, George Mulligan, Dixie-Lee Esseltine, Andrew Cakana, Pier Luigi Zinzani, Ofer Shpilberg, Michael Crump, Sven de Vos, Joanna Romejko-Jarosinska, Adriana Teixeira, Simon Rule, Fritz Offner, Jiri Mayer, Adriana Scheliga, Xiaonan Hong, Evgenii A. Osmanov, Michael E. Schaffer, Helgi van de Velde, Yusri A. Elsayed, Panteli Theocharous, Alice Shapiro, Dana Gaffney, Reyna Favis, Jayaprakash D. Karkera, Erin D. Henitz, Weimin Li, Bertrand Coiffier
Supplementary Table 3 PDF file 70K, Median PFS for patients in the discovery and confirmation sets, and in all patients, in the cross-validation model (see Supplementary Materials) who were positive or negative for the biomarker pair PSMB1 P11A (G al
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::06a292fdb3b594771e795bd003781d77
https://doi.org/10.1158/1078-0432.22448835
https://doi.org/10.1158/1078-0432.22448835
Autor:
Deborah Ricci, George Mulligan, Dixie-Lee Esseltine, Andrew Cakana, Pier Luigi Zinzani, Ofer Shpilberg, Michael Crump, Sven de Vos, Joanna Romejko-Jarosinska, Adriana Teixeira, Simon Rule, Fritz Offner, Jiri Mayer, Adriana Scheliga, Xiaonan Hong, Evgenii A. Osmanov, Michael E. Schaffer, Helgi van de Velde, Yusri A. Elsayed, Panteli Theocharous, Alice Shapiro, Dana Gaffney, Reyna Favis, Jayaprakash D. Karkera, Erin D. Henitz, Weimin Li, Bertrand Coiffier
Purpose: Identify subgroups of patients with relapsed/refractory follicular lymphoma deriving substantial progression-free survival (PFS) benefit with bortezomib–rituximab versus rituximab in the phase III LYM-3001 study.Experimental Design: A tota
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6789c41d2422c276b43ce9da7921147c
https://doi.org/10.1158/1078-0432.c.6521496
https://doi.org/10.1158/1078-0432.c.6521496